WESTON, FL, Oct. 20 /CNW/ - Apotex Corp announced today that it has signed an exclusive distribution agreement with Hisamitsu Pharmaceutical Company of Japan. Apotex will sell to the U.S. healthcare market, Hisamitsu's recently FDA approved matrix Fentanyl Transdermal System for the management of chronic pain.
The Fentanyl Transdermal System, developed by Hisamitsu, is manufactured at the company's state of the art Carlsbad, California facility. The total Fentanyl patch market in the U.S. represents approximately $1.2 billion in sales.
Apotex Corp has a strong sales and marketing group that has positioned the company in the top tier of generic pharmaceutical organizations in the U.S. market. "We are excited to include this important, quality product in our portfolio and to be able to offer it to our valued healthcare partners" stated Jeff Watson, Chief Commercial Officer. The company will announce launch plans at a later date.
Apotex has over 6,000 employees worldwide and produces over 300 medicines in 4,000 dosages, in 21 facilities in North America. Ranked among the top 10 generic companies in the U.S., Apotex plans to spend $2 billion in research and development over the next 10 years. Apotex presently has 600 products in development, and produces quality affordable medicines for healthcare systems in 115 countries.
SOURCE Apotex Inc.
For further information: For further information: US: Steve Giuli, Director, Government Affairs, Apotex Corp, Tel: (954) 384-8007, Ext. 3984, e-mail: firstname.lastname@example.org; Canada: Elie Betito, Director, Public & Government Affairs, Apotex Inc., Tel: (416) 749-9300, Ext. 7366, email: email@example.com